These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32618653)

  • 1. The Impact of the Policy-Practice Gap on Costs and Benefits of Barrett's Esophagus Management.
    Omidvari AH; Roumans CAM; Naber SK; Kroep S; Wijnhoven BPL; Gaast AV; de Jonge PJ; Spaander MCW; Lansdorp-Vogelaar I
    Am J Gastroenterol; 2020 Jul; 115(7):1026-1035. PubMed ID: 32618653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
    Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
    Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
    Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
    Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barrett's oesophagus: a review of costs of the illness.
    Arguedas MR; Eloubeidi MA
    Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
    Provenzale D; Schmitt C; Wong JB
    Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
    Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
    Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis.
    Omidvari AH; Hazelton WD; Lauren BN; Naber SK; Lee M; Ali A; Seguin C; Kong CY; Richmond E; Rubenstein JH; Luebeck GE; Inadomi JM; Hur C; Lansdorp-Vogelaar I
    Gastroenterology; 2021 Aug; 161(2):487-494.e4. PubMed ID: 33974935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance in Barrett's esophagus: a failed premise.
    Inadomi JM
    Keio J Med; 2009 Mar; 58(1):12-8. PubMed ID: 19398879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: results from a randomized controlled trial (SURF trial).
    Phoa KN; Rosmolen WD; Weusten BLAM; Bisschops R; Schoon EJ; Das S; Ragunath K; Fullarton G; DiPietro M; Ravi N; Tijssen JGP; Dijkgraaf MGW; Bergman JJGHM;
    Gastrointest Endosc; 2017 Jul; 86(1):120-129.e2. PubMed ID: 27956164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Barrett's esophagus: a national study of practice patterns and their cost implications.
    Gross CP; Canto MI; Hixson J; Powe NR
    Am J Gastroenterol; 1999 Dec; 94(12):3440-7. PubMed ID: 10606300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
    Gerson LB; Groeneveld PW; Triadafilopoulos G
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer.
    Streitz JM; Ellis FH; Tilden RL; Erickson RV
    Am J Gastroenterol; 1998 Jun; 93(6):911-5. PubMed ID: 9647017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance in Barrett's esophagus: an audit of practice.
    Ajumobi A; Bahjri K; Jackson C; Griffin R
    Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.
    Heberle CR; Omidvari AH; Ali A; Kroep S; Kong CY; Inadomi JM; Rubenstein JH; Tramontano AC; Dowling EC; Hazelton WD; Luebeck EG; Lansdorp-Vogelaar I; Hur C
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1397-1404.e7. PubMed ID: 28238953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barrett's esophagus surveillance: When, how often, does it work?
    Katona BW; Falk GW
    Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):9-24. PubMed ID: 21112494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
    Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to clinical guidelines for Barrett's esophagus.
    Holmberg D; Ness-Jensen E; Mattsson F; Lagergren J
    Scand J Gastroenterol; 2019 Aug; 54(8):945-952. PubMed ID: 31314608
    [No Abstract]   [Full Text] [Related]  

  • 19. A guide for surveillance of patients with Barrett's esophagus.
    Provenzale D; Kemp JA; Arora S; Wong JB
    Am J Gastroenterol; 1994 May; 89(5):670-80. PubMed ID: 8172136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
    Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
    Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.